Pre-RAI Monocyte-to-Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate-Risk DTC, While PNI and NRI Show No Prognostic Value. | Synapse
February 26, 2026
Pre-RAI Monocyte-to-Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate-Risk DTC, While PNI and NRI Show No Prognostic Value.
Key Points
To determine the prognostic value of pre-RAI monocyte-to-lymphocyte ratio in predicting recurrence risk in intermediate-risk DTC.
Analyzed pre-RAI monocyte-to-lymphocyte ratio from patient samples.
Evaluated its association with recurrence risk in intermediate-risk differentiated thyroid cancer.
Compared findings with prognostic values of PNI and NRI.
Identified pre-RAI monocyte-to-lymphocyte ratio as a significant predictor of recurrence risk.
Found that PNI and NRI did not show reliable prognostic value for recurrence.
Indicated that higher pre-RAI MLR correlates with increased recurrence risk in intermediate-risk DTC.
Abstract
Pre-RAI MLR may serve as a simple marker to refine recurrence risk stratification and personalize follow-up in intermediate-risk DTC.